- Not Fee assured
- Verified this account
I am a Consultant Medical Oncologist at the Kent Oncology Centre in Maidstone.
Areas of interest
Specialist in cancers of the thorax and gastrointestinal tract (e.g. lung cancer, mesothelioma, colorectal cancer, oesophageal cancer, pancreatic cancer, gall bladder cancer, stomach cancer); Specialist in unknown primary malignancies and acute oncology; Specialist in phase II and III clinical trials
Current NHS consultant posts held
Consultant Medical Oncologist since 2006 at Kent Oncology Centre, Maidstone. NHS roles at Maidstone and Tunbridge Wells NHS Trust and Darent Valley Hospital
Phase II/III clinical trials of novel therapeutic agents. I have been involved in cancer clinical trials using a range of investigational medicinal products such as BIBW2992, BIBF1120, MAGE A3, NGR-hTNF, Temilumomab, Defactinib, Olaparib Some of these are now licensed drugs.
ASCO Foundation Merit Award 2005
Some interesting publications include:
James Chih-Hsin Yang, Martin H. Schuler, Nobuyuki Yamamoto, Kenneth John O'Byrne, Vera Hirsh, Tony Mok, Sarayut Lucien Geater, Sergey V Orlov, Chun-Ming Tsai, Michael J. Boyer, Wu-Chou Su, Jaafar Bennouna, Terufumi Kato, Vera Gorbunova, Ki Hyeong Lee, Riyaz N.H. Shah, Dan Massey, Robert M. Lorence, Mehdi Shahidi, Lecia V. Sequist. LUX-Lung 3: A randomized, open-label, phase III study of afatinib versus pemetrexed and cisplatin as first-line treatment for patients with advanced adenocarcinoma of the lung harboring EGFR-activating mutations. J Clin Oncol 30, 2012 (suppl; abstr LBA7500)
Marianne Nicolson, Keith M Kerr, Riyaz N.H. Shah, Vanessa Potter, Sunil Upadhyay, Paul Taylor, Scott Myrand, Tuan Stevon Nuguyen, Mayukh Das, Dean Anthony Fennell. Correlation between thymidylate synthetase (TS) expression and progression-free survival (PFS) in patients receiving pemetrexed (pem) for advanced NSCLC: A prospective study. J Clin Oncol 30, 2012 (suppl; abstr 7583
Billingham, Gaunt, Jarrettt, Dunlop, Thompson, O’Byrne, Kumar, Skailes, Nicholson, Shah, Leonard, Chetiyawardana, Wells, Lewanski, Woll, Crosse, Hill, Ferry. Quality of life in advanced non small cell lung cancer, effects of cisplatin dose and Carboplatin in combination with gemcitabine: results from BTOG2, a British Thoracic Oncology Group Phase III trial in 1363 patients. J Thoracic Oncology 2011. 6 (6), Suppl2, S319. Presented at IASLC World Lung Cancer Congress Amsterdam 2011.
Papa S, Popat S, Shah R, Prevost AT, Lal R, McLennan B, Cane P, Lang-Lazdunski L, Viney Z, Dunn JT, Barrington S, Landau D, Spicer J. Phase 2 Study of Sorafenib in Malignant Mesothelioma Previously Treated with Platinum-Containing Chemotherapy. J Thorac Oncol. 2013 Apr 8.
Shah RN, Ibbitt JC, Alitalo K, Hurst HC. FGFR4 overexpression in pancreatic cancer is mediated by an intronic enhancer activated by HNF1alpha. Oncogene. (2002); 28; 21(54): 8251-61.
- BSc Hons and MBBS University of London 1994
- MRCP (UK) Royal College of Physicians of London 1997
- PhD Imperial College London 2002
- FRCP Royal College of Physicians of London 2010
Details of entry to specialist register
- CCT in Medical Oncology, 2005
Post treatment communication
Following treatment of a Bupa member, I will communicate with GPs in line with Department of Health, GMC and appropriate professional bodies guidelines.
Information for healthcare professionals (Bupa patients only, last 12 months)
Clinical supervision and planning for delivery of chemotherapy cycle 1 - 21 days - (5-50)
Clinical supervision and planning for delivery of chemotherapy cycle 1 - 14 days - (5-50)
BMI Chelsfield Park Hospital (5-50)
Clinical supervision and planning for delivery of chemotherapy cycle 1 - 28 days - (5-50)
Maidstone Hospital (5-50)